Affiliation: Bristol-Myers Squibb
- Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderVladimir Coric
Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
Depress Anxiety 27:417-25. 2010..This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD)...
- Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer diseaseVladimir Coric
Neuroscience Global Clinical Research, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
Arch Neurol 69:1430-40. 2012..To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD)...
- Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical TrialVladimir Coric
Global Clinical Research, Bristol Myers Squibb, Wallingford, Connecticut
JAMA Neurol 72:1324-33. 2015..To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild cognitive impairment (MCI) symptoms...